Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 105
- 13F valueReported value at the end of Q2 2026
- $239.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding IKT, Q2 2026
No superinvestor reported holding IKT at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Inhibikase Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 24, 2025 (view filing)3:47 PM ET | Nov 21 | 3 days | Sands Capital Alternatives, LLC and 2 others10% Owner | PPurchase | +2.07M | $1.45 | +$3.00M | +18.9%13.0M after | |
| Oct 23, 2024 (view filing) | Oct 21 | 2 days | Bellini RobertoDirector | PPurchase | +1.46M | $1.37 | +$2.00M | New position1.46M after | |
| Oct 23, 2024 (view filing) | Oct 21 | 2 days | Kush ArvindDirector | PPurchase | +145.0K | $1.37 | +$198.7K | New position145.0K after | |
| Oct 23, 2024 (view filing) | Oct 21 | 2 days | Munshi AmitDirector | PPurchase | +365.0K | $1.37 | +$500.1K | New position365.0K after | |
| Aug 16, 2022 (view filing) | Aug 16 | Same day | Werner Milton H.President and CEO | PPurchase | +5.00K | $0.80 | +$4.00K | +0.1%5.34M after | |
| May 31, 2022 (view filing) | May 27 | 4 days | Werner Milton H.President and CEO | PPurchase | +5.00K | $0.98 | +$4.90K | +0.1%5.33M after | |
| May 23, 2022 (view filing) | May 20 | 3 days | Werner Milton H.President and CEO | PPurchase | +10.0K | $0.60 | +$6.00K | +0.2%5.33M after | |
| May 23, 2022 (view filing) | May 19 | 4 days | Frattaroli JosephChief Financial Officer | PPurchase | +3.95K | $0.64 | +$2.53K | +8.9%48.1K after | |
| Nov 19, 2021 (view filing) | Nov 17 | 2 days | Werner Milton H.President and CEO | PPurchase | +23.6K | $1.97 | +$46.6K | New position23.6K after | 5 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Inhibikase Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sands Capital Ventures, LLC | 13,018,965 | $26.4M | 4.31% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 10,875,000 | $22.1M | 0.76% | 00.0% | Unchanged |
| Trails Edge Capital Partners, LP | 9,051,318 | $18.4M | 2.92% | +993,973+12.3% | Added |
| Fairmount Funds Management LLC | 8,625,000 | $17.5M | 1.16% | 00.0% | Unchanged |
| BlackRock, Inc. | 7,768,057 | $15.8M | 0.00% | +1,464,624+23.2% | Added |
| ADAR1 Capital Management, LLC | 7,387,205 | $15.0M | 0.70% | +780,633+11.8% | Added |
| Blackstone Group Inc. | 5,938,276 | $12.1M | 0.04% | 00.0% | Unchanged |
| Siren, L.L.C. | 5,850,000 | $11.9M | 0.24% | 00.0% | Unchanged |
| Commodore Capital LP | 5,397,488 | $11.0M | 0.65% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 4,935,354 | $10.0M | 0.00% | +484,689+10.9% | Added |